focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,166.00
Bid: 12,132.00
Ask: 12,136.00
Change: -6.00 (-0.05%)
Spread: 4.00 (0.033%)
Open: 12,180.00
High: 12,198.00
Low: 12,076.00
Prev. Close: 12,172.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WRAPUP 9-Markets fall on Omicron fears as officials offer vaccine reassurance

Tue, 30th Nov 2021 03:07

(Adds markets, BioNTech)

* Drugmaker's CEO warns of 'material drop' in effectiveness

* Markets fall on fears of prolonged pandemic, but partly
recover

* Time needed to see if vaccines work against Omicron

* Variant first detected in Netherlands on Nov. 19

* Japan reports first case as new variant spreads

By Ludwig Burger and Emma Thomasson

FRANKFURT/BERLIN, Nov 30 (Reuters) - Financial markets fell
sharply on Tuesday after the head of drugmaker Moderna said
existing COVID-19 vaccines would be less effective against the
new Omicron variant, but they recovered strongly after more
reassuring comments from European officials.

European Medicines Agency (EMA) executive director Emer
Cooke told the European Parliament that existing vaccines will
continue to provide protection.

Andrea Ammon, chair of the European Centre for Disease
prevention and Control (ECDC), said the cases of Omicron so far
confirmed in 10 European Union countries were mild or without
symptoms, although in younger age groups.

The Pan-European STOXX 600 index, spooked by fears that
vaccine resistance https://www.reuters.com/world/how-worried-should-we-be-about-omicron-variant-2021-11-27
might trigger restrictions that would choke off a nascent
recovery, was down 0.5% at around 1644 GMT, having fallen as
much as 1.5% in early trade.

In New York at 1605 GMT, the Dow Jones Industrial Average
and the S&P 500 respectively were down about 1.3%
and 1.26%.

"There is no world, I think, where (the effectiveness) is
the same level?.?.?. we had with Delta," Moderna CEO Stephane
Bancel told the Financial Times https://www.ft.com/content/27def1b9-b9c8-47a5-8e06-72e432e0838f.

"I think it's going to be a material drop. I just don't know
how much because we need to wait for the data. But all the
scientists I've talked to?.?.?.are like 'this is not going to be
good'."

The University of Oxford said there was no evidence that
current vaccines would not prevent severe disease from Omicron https://www.reuters.com/business/healthcare-pharmaceuticals/how-fast-does-it-spread-scientists-ask-whether-omicron-can-outrun-delta-2021-11-29,
but that it was ready to rapidly update its shot, developed
with AstraZeneca, if necessary.

LAB TESTS

Moderna could not be reached for comment.

Regeneron Pharmaceuticals said its COVID-19 antibody
cocktail and other similar antiviral treatments could be less
effective against the latest variant.

News of Omicron's emergence had wiped roughly $2 trillion
off global stocks on Friday, after it was identified in southern
Africa and announced on Nov. 25.

Yet Dutch authorities said the variant had been detected in
the Netherlands as early as Nov. 19, before two flights arrived
from South Africa that were known to have carried the virus.

Cooke said lab tests for "cross neutralisation" would take
about two weeks. If there were a need to change COVID-19
vaccines, new ones could be approved within three or four
months, she added.

"Vaccination will likely still keep you out of the
hospital," said John Wherry, director of the Penn Institute for
Immunology in Philadelphia.

Moderna and fellow drugmakers BioNTech and Johnson & Johnson
are already working on vaccines that specifically target
Omicron. Moderna has also been testing a higher dose of its
existing booster.

BioNTech and Pfizer's vaccine will likely offer
strong protection against severe disease from the new variant,
BioNTech Chief Executive Ugur Sahin told Reuters.

Sahin said he expects lab tests to show some loss of
protection against mild and moderate disease due to Omicron but
the extent of that loss was hard to predict.

But border closures have already cast a shadow over economic
recovery just as parts of Europe see a fourth wave of infections
as winter sets in.

Bank of England policymaker Catherine Mann added to downbeat
comments from U.S. Fed Chairman Jerome Powell by
saying Omicron could hit consumer confidence, which would not
only weaken the British economy's recovery but could also could
push up inflation at the same time.

Many of the new travel restrictions have focused, to South
Africa's fury, on banning flights to and from southern Africa.

Japan confirmed its first case of the new variant on
Tuesday, in a traveller from Namibia. Australia found that a
person with Omicron had visited a busy shopping centre in Sydney
while probably infectious.

BORDER CONTROLS

Britain and the United States have both pushed their booster
programmes in response to the new variant. London said
international arrivals would have to self-isolate until they get
a negative result in a PCR test.

Greece said vaccination would be compulsory for the
over-60s, the group seen as most vulnerable to COVID-19.

Australia on Monday delayed the reopening of its
international borders by two weeks, less than 36 hours before
foreign students and skilled migrants were to be allowed back.

But in Germany, a current hotspot of the previous
significant variant, Delta, the seven-day average infection rate
fell slightly for the first time in three weeks after new
restrictions to slow transmission.

Sources said chancellor-in-waiting Olaf Scholz supported
making vaccination against COVID-19 compulsory and backed
barring the unvaccinated from non-essential stores.

Neighbouring Austria, which imposed its fourth full lockdown
last week after a surge in infections, also registered a drop.

But France registered its highest daily infection tally
since April.

And the Dutch health authority said Omicron was already
spreading in the Netherlands, where intensive care beds are
running out and measures including restrictions on hospitality
have yet to take effect.

The curbs on travellers from southern Africa have
highlighted the inequality of vaccine distribution, which may
have given the virus more opportunities to mutate.

WHO head Tedros Adhanom Ghebreyesus said he understood
concerns about Omicron, but added:

"I am equally concerned that several member states are
introducing blunt, blanket measures that are not evidence-based
or effective on their own, and which will only worsen
inequities."

The passenger liner Europa was docking in Cape Town on
Tuesday in what was meant to be the official start of the first
cruise ship season in South Africa's top tourist hub since the
pandemic.

After Omicron was discovered while they were at sea, many
passengers were expected to fly straight home.

(Reporting by Reuters bureaux worldwide; Writing by Himani
Sarkar and Kevin Liffey; Editing by Shri Navratnam, Andrew
Cawthorne, Nick Macfie and Angus MacSwan)

More News
16 May 2024 10:27

AstraZeneca trials yield positive results for immunocompromised patients

(Alliance News) - AstraZeneca PLC on Thursday said results from recent trials revealed a significant reduction in cases of Covid-19.

Read more
12 May 2024 13:25

Pfizer and AstraZeneca announce new investments of nearly $1 billion in France

PARIS, May 12 (Reuters) - Leading healthcare companies Pfizer and AstraZeneca announced on Sunday new investments in France worth a total of nearly $1 billion, ahead of the start of this year's annual 'Choose France' business summit.

Read more
8 May 2024 19:10

Sector movers: Aerospace and Defence, Pharma pace gains

(Sharecast News) - London's main stock market gauges continued to push higher in the middle of the week, even as investors waited on the Bank of England's policy announcement on the following day.

Read more
8 May 2024 17:46

FTSE 100 hits record high, pound slips ahead of BoE verdict

FTSE 100 up 0.5%, FTSE 250 adds 0.4%

*

Read more
8 May 2024 16:36

London close: Stocks rise further ahead of BoE decision

(Sharecast News) - London's stock markets closed with gains on Wednesday, bolstered by a dip in the value of the pound against both the dollar and the euro.

Read more
8 May 2024 09:44

AstraZeneca says withdraws Covid vaccine "for commercial reasons"

(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemic, citing "commercial reasons" and a surplus of updated jabs.

Read more
8 May 2024 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
7 May 2024 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.